LSTA - צמיחת מכירות ב-12 חודשים נגררים lisata.com

The complexity of biological mechanisms and costly testing ensure that the niche occupied by Lisata Therapeutics (LSTA) remains accessible only to experts. This TTM year-over-year sales growth rate chart visualizes revenue dynamics, where -91.20 characterizes this valuation parameter. Patents for the iCend system and stringent FDA oversight limit competition, while cyclical resilience ensures stable demand for innovation.
פילוחי נתונים אנליטיים מרוכזים עבור lisata.com (LSTA)

Asset managers require an objective tool to evaluate the dynamics of an issuer's cash flows. This metric measures the percentage deviation of current revenue over the last twelve months from the same period last year. Analyzing the change in sales volume relative to the prior year (TTM) helps identify the business's operational resilience to market shocks. For Lisata Therapeutics (LSTA), the volatility of this index reflects the commercial efficiency of developing platforms against solid tumors. Diversification of the cancer research pipeline minimizes the risks of sharp revenue drawdowns.